Inovio Pharmaceuticals
American biotechnology company
Nasdaq
ISIN US45773H4092 SEC CIK 1055726 LEI 529900B9W875XDZXTM97
Follow Inovio Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$298.9K
Net income
−$49.2M
−8.2% vs same quarter last year
EPS, diluted
−$0.50
+42.5% vs same quarter last year
Operating cash flow
−$15.3M
+29.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $65.3K | −$85M |
| FY24 | $217.8K | −$107M |
| FY23 | $832K | −$135M |
| FY22 | $10.3M | −$279.8M |
| FY21 | $1.8M | −$303.7M |
| FY20 | $7.4M | −$166.4M |
| FY19 | $4.1M | −$119.4M |
| FY18 | $30.5M | −$97M |
| FY17 | $42.2M | −$88.2M |
| FY16 | $35.4M | −$73.7M |
| FY15 | $40.6M | −$29.2M |
| FY14 | $10.5M | −$36.1M |
| FY13 | $13.5M | −$66M |
| FY12 | $4.1M | −$19.7M |
| FY11 | $9.8M | −$15.3M |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −132871.3% | −130082.8% |
| FY24 | −51616.9% | −49137.6% |
| FY23 | −17300.3% | −16225.8% |
| FY22 | −2607.4% | −2726.7% |
| FY21 | −16972.3% | −17109.9% |
| FY20 | −1674.2% | −2245.4% |
| FY19 | −2702.1% | −2902.8% |
| FY18 | −308.7% | −318.1% |
| FY17 | −198.1% | −208.9% |
| FY16 | −215.5% | −208.5% |
| FY15 | −84.5% | −71.9% |
| FY14 | −377.7% | −345.4% |
| FY13 | −145.1% | −490.3% |
| FY12 | −570.4% | −477.6% |
| FY11 | −220.9% | −155.7% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$88.9M |
| FY24 | −$104.6M |
| FY23 | −$124.7M |
| FY22 | −$217.2M |
| FY21 | −$216.9M |
| FY20 | −$179.5M |
| FY19 | −$98.8M |
| FY18 | −$75.6M |
| FY17 | −$73.5M |
| FY16 | −$65.3M |
| FY15 | −$15.2M |
| FY14 | −$31.2M |
| FY13 | −$15.6M |
| FY12 | −$22.5M |
| FY11 | −$19.9M |
- Inovio Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Inovio Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | −130082.8% | −30.6% |
| FY24 | −49137.6% | −47% |
| FY23 | −16225.8% | −58% |
| FY22 | −2726.7% | −80.4% |
| FY21 | −17109.9% | −71.9% |
| FY20 | −2245.4% | −62.2% |
| FY19 | −2902.8% | −46.3% |
| FY18 | −318.1% | −49.6% |
| FY17 | −208.9% | −45.9% |
| FY16 | −208.5% | −36% |
| FY15 | −71.9% | −38.4% |
| FY14 | −345.4% | −35.5% |
| FY13 | −490.3% | −37.1% |
| FY12 | −477.6% | −29.1% |
| FY11 | −155.7% | −27.9% |